Trastuzumab Deruxtecan (T-DXd) in metastatic breast cancer with different HER2 expression levels: a real-world effectiveness and safety study

Published: 8 January 2025| Version 1 | DOI: 10.17632/njtcwdd5px.1
Contributor:
Lan Xu

Description

In this study, we aimed to investigate the effectiveness and safety of T-DXd in different HER2 expression patients in real-word setting.

Files

Steps to reproduce

This study was a retrospective observational study. In total, 118 mBC patients with HER2-positive and HER2-low receiving treatment of T-DXd between June 2020 and September 2024 were enrolled. And demographic and clinical characteristics, progression, follow-up dates, and toxicities were collected.

Institutions

Zhejiang Chinese Medical University Affiliated Third Hospital, Zhejiang Cancer Hospital

Categories

Clinical Analysis

Licence